Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Return on Capital Employed (2017 - 2025)

Rein Therapeutics (RNTX) has disclosed Return on Capital Employed for 9 consecutive years, with 1.22% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed fell 93.0% to 1.22% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.22%, a 93.0% decrease, with the full-year FY2024 number at 0.83%, down 56.0% from a year prior.
  • Return on Capital Employed was 1.22% for Q3 2025 at Rein Therapeutics, up from 1.23% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.19% in Q1 2024 to a low of 1.45% in Q1 2023.
  • A 5-year average of 0.81% and a median of 0.84% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: soared 126bps in 2024, then plummeted -99bps in 2025.
  • Rein Therapeutics' Return on Capital Employed stood at 0.56% in 2021, then tumbled by -131bps to 1.3% in 2022, then skyrocketed by 77bps to 0.3% in 2023, then tumbled by -184bps to 0.84% in 2024, then plummeted by -45bps to 1.22% in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Return on Capital Employed are 1.22% (Q3 2025), 1.23% (Q2 2025), and 1.18% (Q1 2025).